Trial
NCT04141995
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
University of Nebraska
Collaborators
National Cancer Institute (NCI)
Condition
Pancreas Cancer
Intervention
Digoxin
Why stopped
Due to low accrual and futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-07